Get the Stockscreener App
0.76
3.01%
-0.0236
Citius Oncology Inc stock is traded at $0.76, with a volume of 3,809.
It is down -3.01% in the last 24 hours and down -11.21% over the past month.
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
See More
Previous Close:
$0.7836
Open:
$0.76
24h Volume:
3,809
Relative Volume:
0.04
Market Cap:
$80.38M
Revenue:
$5.61M
Net Income/Loss:
$-42.51M
P/E Ratio:
-1.6309
EPS:
-0.466
Net Cash Flow:
$-16.86M
1W Performance:
-8.98%
1M Performance:
-11.21%
6M Performance:
-8.43%
1Y Performance:
-55.81%
1-Day Range:
$0.76
$0.7699
1-Week Range:
$0.7425
$0.8799
52-Week Range:
$0.4912
$2.25
Citius Oncology Inc Stock (CTOR) Company Profile
Name
Citius Oncology Inc
Sector
Phone
(908) 967-6677
Address
11 COMMERCE DRIVE, CRANFORD
Compare CTOR vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
0.76 | 80.38M | 5.61M | -42.51M | -16.86M | -0.466 |
TAK
Takeda Pharmaceutical Co Adr
|
19.64 | 62.73B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.26 | 48.12B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.965 | 43.82B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
78.69 | 32.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.00 | 23.55B | 3.17B | 1.29B | 1.01B | 27.09 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-25 | Upgrade | Maxim Group | Hold → Buy |
| Nov-27-24 | Initiated | Maxim Group | Buy |
Citius Oncology Inc Stock (CTOR) Latest News
Citius Oncology Announces Results of 2026 Annual Stockholder Meeting Votes - Kalkine Media
Citius Pharmaceuticals at Moody Capital conference: launch gains traction By Investing.com - Investing.com Canada
Citius Pharmaceuticals at Moody Capital conference: launch gains traction By Investing.com - Investing.com UK
CTXR Stock Price, Quote & Chart - ChartMill
Citius Pharma CEO to speak at two New York conferences - Stock Titan
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences - PR Newswire
CITIUS ONCOLOGY, INC. SEC Filing (Aug 26, 2026) - Stock Titan
Citius (CTOR) Quarterly Results: The EPS Result Is Below Expectation in the Latest Session; Session Move: Shares Finish 2.02% Lower on the DayEPS Surprise History - vinanet.vn
Enterprise value to EBIT forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Armistice Capital Expands Citius Oncology (CTOR) Stake Despite Distress Signals - GuruFocus
Citius (CTOR) Quarterly Results: Reported EPS Misses Expectations in the Reported Period; After Results: The Market Price Advances 6.97% on the DayForward Guidance Trends - vinanet.vn
Citius Oncology Shares Slide 10% After Fiscal Q3 Revenue Misses Estimates Despite LYMPHIR Launch Gains - dars.gov.et
Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum - Yahoo Finance
Citius Oncology stock tumbles 10% on revenue miss despite launch progress - Investing.com Australia
Citius Oncology stock tumbles 10% on revenue miss despite launch progress - Investing.com
Citius Oncology stock tumbles 10% on revenue miss despite launch progress - Investing.com
Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination - The Clinical Trial Vanguard
CTOR Q2 2026 Earnings: Pre-Revenue Loss Misses Badly, Yet Shares Jump 10%EBITDA Analysis - vinanet.vn
Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR) - simplywall.st
Citius Pharma Reports First LYMPHIR Revenue of $7.1M in Nine Months - minichart.com.sg
Citius Oncology Posts First Revenue from LYMPHIR Launch as Institutional Demand Surges 31% - Minichart
Citius Oncology (NASDAQ:CTOR) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Citius Oncology (CTOR) director Jonathan Peri files Form 3 showing no common shares - Stock Titan
Citius Pharma Q3 EPS beats estimate, sales miss by 72% - scanx.trade
Citius Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress - Intellectia AI
CTOR: LYMPHIR launch drove $7.1M revenue and 31% sequential vial order growth, with broad payer access - TradingView
Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss - Stock Titan
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - PR Newswire
Citius Oncology (CTOR) Advances 5.5% to $0.87 as Buyers Defend Support ZoneInverse ETF Flow - vinanet.vn
Citius Oncology (CTOR) investor reports 9.99% beneficial ownership stake - Stock Titan
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - PR Newswire
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Citius Oncology (CTOR) Advances 5.5% to $0.87 as Buyers Defend Support ZoneRSI Oversold Picks - siam.in
Citius Oncology (CTOR) Advances 5.5% to $0.87 as Buyers Defend Support ZoneIsland Reversal - dars.gov.et
Citius Pharmaceuticals (CTXR) holders report 3.0M-share, 9.9% beneficial stake - Stock Titan
Citius Oncology appoints independent director Peri to board of directors - ROI-NJ
Citius Oncology appoints Jonathan Peri to board of directors By Investing.com - Investing.com Australia
People on the Move: Jonathan Peri, Ph.D., J.D., Joins Citius Oncology’s Board of Directors - BioBuzz
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - Morningstar
Citius Pharmaceuticals expands Citius Oncology board to nine with appointment of Jonathan Peri - Traders Union
Form 8K Citius Oncology Inc For: 12 August By Investing.com - Investing.com South Africa
Form 8K Citius Oncology Inc For: 12 August By Investing.com - Investing.com Australia
Form 8K Citius Oncology Inc For: 12 August By Investing.com - Investing.com Canada
Form 8K Citius Oncology Inc For: 12 August By Investing.com - Investing.com Nigeria
Citius Oncology adds independent director to expanded board - TipRanks
Citius Oncology appoints Jonathan Peri to board of directors By Investing.com - Investing.com Nigeria
Citius Oncology appoints Jonathan Peri to board of directors By Investing.com - Investing.com India
Citius Oncology appoints Jonathan Peri to board of directors By Investing.com - Investing.com Australia
Citius Oncology Adds Jonathan Peri to Board as LYMPHIR Commercialization Advances - citybiz
Citius Oncology Inc Stock (CTOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.23%
10.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):